Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have a history of Heart Failure and have either been hospitalised for it at least once, or have shown clear signs of Heart Failure (such as fluid build-up or pressure problems in the heart) that required water tablets (diuretics) as treatment, along with certain elevated heart-related protein levels in the blood (BNP or NT-proBNP above specific thresholds).
- People who are suspected to have a type of heart disease caused by a protein build-up called ATTR amyloidosis.
- People whose heart scans (echocardiogram) show a specific thickening of the heart wall (the wall between the two lower chambers is more than 12 mm thick).
- People who have signed a consent form agreeing to take part.
- People who are using an accepted method of contraception.
Who may not be able to join:
- People whose Heart Failure is at the most severe level (Class IV on a standard medical scale) even after taking water tablets (diuretics).
- People whose heart amyloidosis or other health conditions mean their life expectancy is estimated to be less than 6 months.
- People who have had their aortic heart valve replaced (by surgery or a keyhole procedure) within the last 30 days, or who have this procedure planned in the coming months.
- People who have a different type of amyloidosis called primary (light chain or AL) amyloidosis.
- People for whom the study medication tafamidis is medically unsuitable or not recommended.
- People who are pregnant or breastfeeding, or women of childbearing age who receive a positive pregnancy test (regardless of contraception use).
- Adults who are under a legal protective measure (such as guardianship or court-appointed protection) (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 33230165709
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Test-retest reproducibility; Correlations between the quantitative assessment of the myocardial uptake of bone tracers and semi-quantitative approaches; Comparison between the quantitative assessment of the myocardial uptake of bone tracers (COV) between baseline and follow-up imaging of each patient, 6 months after the beginning of the treatment by tafamidis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.